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Abstract: Cisplatin, a major antineoplastic drug used in the treatment
of solid tumors, is a known nephrotoxin. This retrospective cohort study
evaluated the prevalence and severity of cisplatin nephrotoxicity in 54
children and its impact on height and weight.
We recorded the weight, height, serum creatinine, and electrolytes in
each cisplatin cycle and after 12 months of treatment. Nephrotoxicity
was graded as follows: normal renal function (Grade 0); asymptomatic
electrolyte disorders, including an increase in serum creatinine, up to 1.5
times baseline value (Grade 1); need for electrolyte supplementation<3
months and/or increase in serum creatinine 1.5 to 1.9 times from
baseline (Grade 2); increase in serum creatinine 2 to 2.9 times from
baseline or need for electrolyte supplementation for more than 3 months
after treatment completion (Grade 3); and increase in serum creatinine
3 times from baseline or renal replacement therapy (Grade 4).
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4 nephrotoxicity. Nephrotoxicity patients were younger and received
higher cisplatin dose, they also had impairment in longitudinal growth
manifested as statistically significant worsening on the height Z Score at
12 months after treatment. We used a multiple logistic regression model
using the delta of height Z Score (baseline-12 months) as dependent
variable in order to adjust for the main confounder variables such as:
germ cell tumor, cisplatin total dose, serum magnesium levels at 12
months, gender, and nephrotoxicity grade. Patients with nephrotoxicity
Grade 1 where at higher risk of not growing (OR 5.1, 95%CI 1.07–24.3,
P¼ 0.04). The cisplatin total dose had a significant negative relationship
with magnesium levels at 12 months (Spearman r¼0.527,
P¼<0.001).
(Medicine 94(34):e1413)
Abbreviations: AKI = acute kidney injury, GFR = glomerular
filtration rate, Z Score = standard deviation score.
INTRODUCTION
T he success in cancer therapy has increased the remissionrate and survival time of patients, it is now common
that cancer survivors face the chronic effects of treatment such
as ototoxicity, neurotoxicity, nephrotoxicity, and skeletal
dysfunction.1–6
Cisplatin is a commonly used antineoplastic drug in the
treatment of solid tumors. It binds to deoxyribonucleic acid
(DNA), leading to intra- and interstrand cross-links that result in
defective DNA templates and interfere with DNA synthesis and
replication.7,8 It also affects mitochondria by inhibiting ATPase
activity and causing apoptosis, oxidative stress, inflammation,
and necrosis. It can be ototoxic, myelotoxic, gastrotoxic, neu-
rotoxic, and nephrotoxic.9,10
In the kidney, the main damage occurs in the renal
tubules.11 The most common adverse effects of tubular damage
include hypomagnesemia, hypophosphatemia, hyponatremia,
hypocalcemia, normoglycaemic-glucosuria, proteinuria, meta-
bolic acidosis including Fanconi syndrome, and nephrogenic
diabetes insipidus. Cisplatin can also produce glomerular
damage (thrombotic microangiopathy) and acute kidney injury
(AKI) as a result of acute tubular injury/necrosis, which can
further progress to chronic kidney disease.3,12
Cytotoxic chemotherapy treatment has been linked to
delayed longitudinal growth in children with cancer.13 Bone
is the main repository of minerals in the body including calcium,
phosphorus, magnesium, and trace elements. Bone formation is
directly linked to longitudinal growth and in animal models
cisplatin has shown to inhibit new bone formation.14 Data have
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also been published indicating that after standard cisplatin
chemotherapy is completed, platinum exposure continues for
at least 20 years. Whether chronically elevated platinum con-
centrations influence the development of these or other late
toxicities including secondary malignancies is unknown.15
The aim of our study was to evaluate the prevalence and
severity of cisplatin nephrotoxicity in children and to determine
the impact of nephrotoxicity on growth.
PATIENTS AND METHODS
Study Participants and Design
Retrospective study of children treated with cisplatin for
solid tumors that were part of a cohort studied for adverse
reactions to chemotherapy, approved by the Hospital IRB and
Ethics Committee at the Hospital Infantil de Me´xico Federico
Go´mez. This large public hospital receives patients referred
from across the country. All patients or parents provided written
informed consent.
Patients treated for childhood cancer (18 years of age at
the start of therapy) received cisplatin therapy between June
2002 and May 2013.
The information about weight, height, serum creatinine,
and electrolytes (magnesium, phosphorus, and potassium)
before each cisplatin cycle and after 12 months of treatment
was obtained from the medical record. We excluded patients
with incomplete information.
The standard deviation score (Z Score) for height and
weight was calculated with the app STAT GrowthCharts version
3.2 that uses the National Center for Health Statistics 2000
Center for Disease Control Growth Data.16 The Z Score was
obtained by subtracting the actual patient weight or height from
the mean weight or height of the population of that chrono-
logical age and gender divided by the appropriate standard
deviation. A Z Score of 0 means that the patient has the average
height or weight for age and gender. Values below2.0 orþ2.0
are outside normal growth charts.
Glomerular filtration rate (GFR) was estimated using
Schwartz formula as serum creatinine was measured by Jaffe
method.17 Hypomagnesemia was defined as Mg values
<1.5mg/dL. It was considered severe when Mg is 1.0mg/
dL.18 Hypophosphatemia was defined when phosphate values
below age recommended values by the National Kidney
Foundation clinical practice guidelines (KDIGO):19
6 to 12 months 5.0 to 7.8mg/dL; 1 to 5 years 4.5 to 6.5mg/dL; 6
to 12 years 3.6 to 5.8mg/dL; and 13 to 20 years 2.3 to 4.5mg/
dL. Hypokalemia was defined when potassium values below
age recommended values:20 1 month to 2 years 3.7 to 5.9mEq/
L; >2 years to 18 years 3.5 to 5.0mEq/L.
Nephrotoxicity Definition
There are no standards to identify drug-induced kidney
disease. We decided to grade nephrotoxicity considering a score
that combines AKI definition21 and tubulopathy, manifested as
electrolyte disturbances as follows: normal renal function
(Grade 0); asymptomatic electrolyte disorders (hypomagnese-
mia, hypokalemia or hypophosphatemia), including an increase
in serum creatinine, up to 1.5 times baseline value (Grade 1);
need for electrolyte supplementation (magnesium, potassium,
or phosphate) <3 months and/or increase in serum creatinine
Jime´nez-Triana et al1.5 to 1.9 times from baseline (Grade 2); increase in serum
creatinine 2 to 2.9 times from baseline or need for electrolyte
supplementation (magnesium, potassium, or phosphate) for
2 | www.md-journal.commore than 3 months after treatment completion (Grade 3);
and increase in serum creatinine 3 times from baseline or
renal replacement therapy (Grade 4).
The decision to initiate electrolyte supplementation was
made by the treating oncologist.
A clinical pharmacologist, a pediatric nephrologist, a
pediatric oncologist, and an adverse drug reaction surveillance
clinician performed the clinical characterization.
Statistical Analysis
Descriptive statistics is reported as means and standard
deviations or median (25th, 75th percentile) for continuous
measures and percentages for binary/categoricalmeasures. Differ-
ences between nephrotoxicity and nonnephrotoxicity patients
were performed using Student’s t-test, Mann–Whitney, or Fisher
exact test depending upon the variable. Cisplatin total dose and
nephrotoxicity grading was compared by Kruskal–Wallis test.
Height andweight Z Score at baseline versus Z Score at 12months
of treatment was compared using paired t-test.
Repeated measures analysis of variance with Bonferroni
post-test or Friedman test, depending upon the distribution of
the variable, was used to analyze electrolyte, creatinine, and
estimated GFR (eGFR) changes overtime.
Correlations between cisplatin dose and electrolyte levels
at 12 months were determined by Pearson correlation coeffi-
cient. For all tests a P value <0.05 (2-sided) was considered
statistically significant. All statistical analyses were performed
using statistical analysis software (GraphPad Prism for MacOs
X version 5.0).
For multivariate analysis we used a multiple logistic
regression model using the delta of height Z score (baseline–
12 months) as dependent variable in order to adjust for the main
confounder variables such as germ cell tumor, cisplatin total
dose, serum magnesium at 12 months, gender, and nephrotoxi-
city grade. We used the SPSS version 20 for Mac (IBM
Corporation, Armonk, NY).
RESULTS
Patient Characteristics
We collected data on 61 cisplatin-treated patients that
participated in the adverse drug event studies. Seven patients
were excluded, 3 of them because of incomplete medical
information in the clinical chart, and 4 because they did not
complete cisplatin treatment. We have complete information for
54 patients (Figure 1). No patient received growth hormone.
Nephrotoxicity
Patient demographics are outlined in Table 1. Nephrotoxi-
city was observed in 41 patients (76%). No nephrotoxicity
(Grade 0) was observed in 13 patients (24%). Grade 1 nephro-
toxicity was observed in 18 patients (33.3%), Grade 2 in 5
patients (9.2%), and Grade 3 in 18 patients (33.3%). None had
Grade 4 nephrotoxicity. Only 5 patients showed an increase in
serum creatinine, 4 of them 1.5 to 1.9 from baseline and only
one 2.5 times from baseline, all of them required electrolyte
supplements, one patient recovered to baseline serum creatinine
at 12 months of follow-up. The severity of nephrotoxicity was
related to the cisplatin total dose (Figure 2), Kruskal–Wallis
P¼ 0.008.
Medicine  Volume 94, Number 34, August 2015Hypophosphatemia was found in 35 patients (65%), hypo-
magnesemia in 22 (40.7%), and hypokalemia in 20 patients
(37%). Combined hypomagnesemia and hypophosphatemia
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
Medicine  Volume 94, Number 34, August 2015 Cisplatin Nephrotoxicity in Childrenwas observed in 19 patients (35%) and 8 had hypomagnesemia,
hypophosphatemia, and hypokalemia (14.8%).
Patients with nephrotoxicity were younger than patients
with nonnephrotoxicity, median age 5.4 versus 13.8 years,
respectively (P¼ 0.003), they received higher number of cis-
FIGURE 1. Flow diagram of the patients enrolled in the study.platin cycles and therefore higher cisplatin total dose (mean
accumulated dose in nephrotoxicity 455 versus 372mg/m2 in
nonnephrotoxicity, P¼ 0.01). Patients with nephrotoxicity had
TABLE 1. Patient Characteristics
No Ne
Gender (n, %)
Male
Female
Tumor type
Germinal tumor
Hepatoblastoma
Osteosarcoma
Neuroblastoma
Rhabdomyosarcoma
Hepatocarcinoma
Pancreatoblastoma
Age in years (median, 25th 75th percentile)
Cisplatin dose mg/m2BSA (meanSD)
Number of cisplatin cycles (meanSD)
Radiotherapy involving thoracic or abdominal area (n, %)
Long term outcome (n, %)
Palliative care/death
Alive
SD¼ standard deviation.
P value obtained by Fisher exact test, Student’s t-test, or Mann–Whit
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.more diverse tumors than nonnephrotoxicity patients in whom
germinal tumors were more frequent (Table 1).
Concomitant Medications
There was no difference in the concomitant medications
administered to nephrotoxicity and nonnephrotoxicity patients
(Table 2). Three patients from nonnephrotoxicity and 7 patients
phrotoxicity (n¼ 13) Nephrotoxicity (n¼ 41) P Value
3 (23%) 24 (58.5%) 0.057
10 (77%) 17 (41.5%)
9 (69%) 10 (24%) 0.003
3 (23%) 13 (32%) 0.73
1 (8%) 10 (24.4%) 0.26
– 5 (12%) 0.32
– 1 (2.4%) 1.0
– 1(2.4%) 1.0
– 1 (2.4%) 1.0
13.8 (7.3, 16) 5.4 (2.2, 9.6) 0.003
372.6 106 455 101 0.014
4.0 1.2 5.1 1.2 0.011
0 (0%) 3 (7%) 0.57
1.0
1 (7.7%) 6 (14.6%)
12 (92.3%) 35 (85.4%)
ney as appropriate.
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After the 12 months, 1 patient in the nonnephrotoxicity
FIGURE 2. Cisplatin total dose and nephrotoxicity grade. Box and
whisker plots show the 10th, 25th, 50th (median), 75th, and 90th
Jime´nez-Triana et alfrom nephrotoxicity group received amikacin/cefipime twice
during the 1st year of chemotherapy.
Serum Electrolytes and Glomerular Filtration
Rate Follow-up
Values of serum electrolytes, creatinine, and eGFR by
Schwartz formula at baseline, 2nd, 3rd, 4th cisplatin cycle, and
12 months of follow-up are shown in Table 3. Phosphorus
values showed a ‘‘U’’ shape overtime, starting with
4.43 0.77mEq/L, reaching the lowest value at the 3rd cispla-
tin cycle with 4.0 0.90mEq/L and the highest value at 12
months (4.74 1.13mEq/L). Phosphorus values were statisti-
cally significant different at the 2nd, 3rd, and 4th cisplatin
percentile. The severity of nephrotoxicity increased with the
cumulative dose (Kruskal–Wallis P¼0.008).cycles than at 12 months.
Magnesium level decreased each visit in a progressive
way, being significantly lower at the 3rd cycle and at 12 months
TABLE 2. Cisplatin Nephrotoxicity and Concomitant
Medications (n, %)
No
Nephrotoxicity
(n¼ 13)
Nephrotoxicity
(n¼ 41) P Value
Amikacin 5 (38.5%) 19 (46.3%) 0.75
Vancomycin 1 (7.7%) 7 (17%) 0.66
Amphotericin 1 (7.7%) 4 (9.7%) 1.0
Cefepime 4 (30.8%) 12 (29.2%) 1.0
Meropenem 1 (7.7%) 9 (21.9%) 0.41
Cyclophosphamide 8 (61.5%) 16 (39%) 0.20
Doxorubicin 12 (92.3%) 34 (82.9%) 0.66
Vincristine 1 (7.7%) 6 (14.6%) 1.0
Ifosfamide 1 (7.7%) 6 (14.6%) 1.0

Obtained by Fisher exact test.
4 | www.md-journal.comcompared to baseline. Patients started cisplatin treatment with a
magnesium level of 2.02 0.23 and 1.83 0.30mg/dL at
12 months.
There was no statistically significant difference in serum
potassium, creatinine, and eGFR. It is worth noting eGFR was
not normally distributed and 12 patients had hyperfiltration
(eGFR >150mL/min/1.73m2BSA).
Weight and Height Z Score
Patients without nephrotoxicity maintained their height Z
Score after 12 months of treatment (baseline 1.37 1.0, 12
months1.56 0.8, paired t-test P¼ 0.95, Figure 3A), whereas
those with nephrotoxicity had worse height Z Scores after 12
months. Z Scores were more pronounced in those with nephro-
toxicity Grade 1 (baseline0.33 1.2, 12 months1.15 1.1,
P¼ 0.01, Figure 3B) than Grades 2 and 3 (baseline0.34 1.0
vs 12 months 0.8 1.1, P¼ 0.04, Figure 3C). There was no
difference in weight Z Score (basal vs 12 months) in all groups
(Figure 3D–F).
The results of the multivariate logistic analysis of risk
factors for the lack of longitudinal growth are shown in Table 4.
Patients with nephrotoxicity Grade 1 where at higher risk of not
growing (OR 5.1, 95% CI 1.07–24.3, P¼ .04).
Cisplatin Total Dose and Correlation With
Electrolytes at 12 months
The cisplatin total dose had a significant negative relation-
ship with magnesium, potassium, and phosphate levels at 12
months, being statistically significant only for magnesium
(Figure 4A, Spearman correlation 0.527, P¼<0.001).
Patient Follow-Up
Medicine  Volume 94, Number 34, August 2015(Grade 0) group was in palliative care, 4 patients in the group
with nephrotoxicity died, and 2 went to palliative care.
DISCUSSION
Our study confirms a high frequency (76%) of nephro-
toxicity in cisplatin-treated children. In order to evaluate the
cisplatin nephrotoxicity we propose a score that combines the
AKI criteria considering the increase in baseline creatinine21
with an evaluation of the tubulopathy manifested as electrolyte
disturbances, as this latter is the main and most frequent
manifestation of cisplatin nephrotoxicity, but we included not
only magnesium as Skinner et al have suggested11,22 but also
phosphate and potassium.
Grade 1 (asymptomatic, nontreated electrolyte disturb-
ances) and Grade 3 nephrotoxicity (increase in serum creatinine
at 12 months 2–2.9 times from baseline or need for electrolyte
supplementation for more than 3 months after treatment com-
pletion) had the same frequency, 33.3% in our study.
Nephrotoxicity patients received higher cisplatin dose as
has been reported in other studies.11,23
An acute reduction in GFR with the respective increase in
serum creatinine has been reported in 20% to 80% of cisplatin-
treated children, with a GFR at 10 years after treatment
<60mL/min/1.73m2 in 11%.22 In our study we found that
9.2% (5 patients) had an acute reduction in eGFR. Probably the
proportion would be higher if we were able to use the new
Schwartz bedside formula, a more precise equation to estimate
GFR, unfortunately in our center serum creatinine is still
measured by Jaffe method.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 3. Cisplatin Cycle, Renal Function, and Electrolyte Levels
Baseline 2nd Cycle 3rd Cycle 4th Cycle 12 months P Value
Potassium, mEq/L 4.09 0.43 4.24 0.53 4.11 0.62 4.18 0.64 4.06 0.49 0.49
Phosphorus, mEq/L 4.43 0.77 4.01 0.85 4.00 0.90 4.16 0.89 4.74 1.13 0.0001
Magnesium, mEq/L 2.02 0.23 1.95 0.26 1.86 0.31 1.88 0.30 1.83 0.30 0.007
eGFR, mL/min/1.73m2BSA 115.3 (99, 146) 127.4 (108, 161) 131.1 (109, 167) 121.3 (97, 153) 133.2 (111, 165) 0.15
Serum creatinine, mg/dL 0.55 0.19 0.51 0.22 0.51 0.22 0.55 0.21 0.49 0.19 0.60
Values as mean standard deviation (SD) or median (25th, 75th percentile).P value obtained by repeated measures ANOVA (Bonferroni post-test)
or Friedman test depending upon the distribution of the variable. Bonferroni P< 0.05 for 2nd, 3rd, and 4th cycle versus 12 months, Bonferroni
Medicine  Volume 94, Number 34, August 2015 Cisplatin Nephrotoxicity in ChildrenHypomagnesemia has been pointed out as the most com-
monmanifestation of tubular toxicity present in 12% to 100% of
cisplatin-treated patients.23 Nevertheless in the present study,
using the KDIGO age-dependent phosphate values,19 hypopho-
sphatemia was more frequent (65%) and persistent than hypo-
magnesemia (40.7%) in cisplatin-treated children. Ariceta
et al23 demonstrated that all children treated with cisplatin
present increased magnesiuria immediately after therapy, with
a minimal dose to induce hypomagnesemia of 300mg/m2BSA.
We found that cisplatin total dose had a significant negative
correlation with magnesium serum levels after 12 months
of treatment.
We found that patients with nephrotoxicity have impair-
ment in longitudinal growth manifested as statistically signifi-
P< 0.05 baseline versus 3rd cycle and baseline versus 12 months.cant worsening on the height Z Score at 12 months after
treatment, interestingly, patients with nephrotoxicity Grade 1
(asymptomatic, not treated) were the most affected.
FIGURE 3. Nephrotoxicity grading and meanSE of height Z Score
cisplatin treatment. P value obtained by paired t-test.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Our study has limitations such as the retrospective design,
the small number of patients, single center, the lack of a control
group of children with solid tumors not treated with platinum
compounds, and absence of information about Tanner stage and
nutritional status. The strength is that all patients had serum
electrolyte and creatinine results before each cisplatin cycle and
in the 12-month follow-up period.
Cisplatin was introduced in medical practice in 1970. The
importance of hydration and electrolyte supplementation during
infusion to prevent adverse events was described and integrated
to management protocols in the 1980s and 1990s. During the
study period (2002–2013) cisplatin infusion itself was provided
in similar way, nevertheless there have been other improve-
ments in the treatment of cancer patients at our Institution such
as the related to surgical techniques, the use of filgastrim for
neutropenia and the availability of a linear accelerator for
targeted radiation therapy since 2010. Any of these changes
(A, B, C) and weight (D, E, F) at baseline and after 12 months of
www.md-journal.com | 5
33,34
lyte
TABLE 4. Multivariate Logistic Analysis of Risk Factors for the Lack of Longitudinal Growth at 12 months After Cisplatin Therapy
Covariate Beta-Coefficient Odds Ratio 95% CI P Value
Nephrotoxicity grade
Grade 1 1.63 5.12 1.07–24.3 0.040
Grade 2 0.836 0.434 .034–5.53 0.520
Grade 3 0.972 2.64 .491–14.2 0.258
Cisplatin total dose, mg/m2/BSA 0.001 1.00 1.000–1.003 0.120
Germ cell tumor 0.408 1.50 .380–5.95 0.561
Serum magnesium at 12 months 0.793 2.21 .292–16.74 0.443
Gender 1.12 0.325 .094–1.31 0.077
Jime´nez-Triana et al Medicine  Volume 94, Number 34, August 2015could improve cancer outcomes and reduce complete reliance
on cisplatin to treat solid tumors.
Childhood and adolescence are crucial times to acquire the
peak bone mass. Phosphate is a key component of the hydro-
xiapatite crystals (Ca10(PO4)6(OH)2) in the bone mineral
phase.24 Magnesium is also important mineral in bone health,
and its depletion is related to low parathyroid hormone and bone
demineralization.25–27
We suggest that the observed impairment in longitudinal
growth in patients with nephrotoxicity may be due to phos-
phate and magnesium urinary losses; patients with asympto-
matic, nontreated electrolyte abnormalities (nephrotoxicity
Grade 1) are at higher risk of lack of longitudinal growth,
cisplatin total dose has a negative relationship with magnes-
ium serum levels at 12 months. There are studies in animal
models that suggest that hypomagnesemia enhances cisplatin
accumulation in renal tissue by upregulating the organic
cation transporter 2 (OCT2) transporter.28 Circulating levels
of cisplatin have been shown up to 20 years after therapy, thus
long-term renal effects are expected.15,29
The molecular mechanisms of cisplatin-induced damage
in the nonproliferating renal tubular cells are not fully under-
stood. Cisplatin clearance by the kidney depends upon glo-
merular filtration and tubular secretion. Cisplatin accumulates
in the kidney at higher concentrations than in the blood and
other organs, contributing to kidney injury. This high drug
concentration is attributed to several membrane transporters
(Copper transporter 1 -CTR1/SLC31A1-, copper-transporting
FIGURE 4. Correlation of cisplatin total dose and serum electro
phosphate.ATPase 1 -ATP7A-, copper-transporting ATPase 2 –ATP7B-,
multidrug and toxin extrusion protein 1 – MATE1/SLC47A1-,
OCT2).30–32
6 | www.md-journal.comFurther studies are needed to identify if genetic variants
can predict the nephrotoxicity risk, as occur with the ototoxi-
levels at 12 months. (A) Magnesium, (B) potassium, and (C)city, and importantly if electrolyte supplementation can
prevent the deleterious effect of nephrotoxicity on longitudinal
growth and bone health.
ACKNOWLEDGMENTS
The authors thank Fondos Federales Hospital Infantil de
Me´xico Federico Go´mez, HIM/2011/016 and HIM/2013/026.
Mara Medeiros received a CONACYT grant 205627 for the
support. The authors also thank the contributions of the Cana-
dian Pharmacogenomics Network for Drug Safety (CPNDS)
consortium for the discussion of the definition of cisplatin
nephrotoxicity. The CPNDS consortium includes 13 pediatric
academic health centres across Canada. Participants are
arranged geographically by institution across Canada. Van-
couver: BC Children’s Hospital, Child & Family Research
Institute, CMMT, POPi: Michael Hayden, Bruce Carleton,
Colin Ross, Stuart MacLeod, Wyeth Wasserman, Craig Mitton,
Anne Smith, Claudette Hildebrand, Lucila Castro Pastrana,
Reza Ghannadan, Shahrad Rod Rassekh, Jonathan Lim, Fudan
Miao, Henk Visscher, Kusala Pussegoda, Folefac Aminkeng,
Michelle Higginson, Nasim Massah, Mojgan Yazdanpanah,
Johanna Sistonen, Ricardo Jimenez, Adrienne Borrie, Ursula
Amstutz, Shevaun Hughes, Kaitlyn Shaw, Marie deHaan, Satvir
Dhoot, Amit P Bhavsar, Yuling Li, JongW Lee. Calgary: Alberta
Children’s Hospital: Cheri Nijssen-Jordan, David Johnson,
Linda Verbeek, Rick Kaczowka, Patti Stevenson, Andrea Hur-
ton, Carnation Zhuwaki. Edmonton: Stollery Children’s Hos-
pital: Paul Grundy, Kent Stobart, Bev Wilson, Sunil Desai,
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
Maria Spavor, Linda Churcher, Terence Chow. Winnipeg: Win-
nipeg Health Sciences Centre: Kevin Hall, Nick Honcharik,
Sara Israels, Shanna Chan, Byron Garnham, Michelle Staub.
London: London Health Sciences Centre: Michael Rieder,
Becky Malkin. Hamilton: McMaster Children’s Hospital: Carol
Portwine, Amy Cranston. Toronto: Hospital for Sick Children:
Gideon Koren, Shinya Ito, Paul Nathan, Mark Greenberg,
Facundo Garcia Bournissen, Miho Inoue, Sachi Sakaguchi,
Toshihiro Tanaka, Hisaki Fujii, Mina Ogawa, Ryoko Ingram,
Taro Kamiya, Smita Karande, Sholeh Ghayoori. Kingston:
Kingston General Hospital: Mariana Silva, Stephanie Willing.
Ottawa: Children’s Hospital of Eastern Ontario: Re´gis Vail-
lancourt, Pat Elliott-Miller, Donna Johnston, Herpreet Mankoo,
Elaine Wong, Brenda Wilson, Lauren O’Connor, Caleb Hui,
Cindy Yeun. Health Canada: Maurica Maher. Montre´al: Hoˆpi-
tal Sainte-Justine: Jean-Francois Bussie`res, Denis Lebel, Pierre
Barret, Aure´lie Closon, Eve Coulson, Lena Cerruti. Montreal
Heart Institute: Marie-Pierre Dube´, Michael Phillips. McGill
University Health Centre-Montre´al Children’s Hospital: Nada
Jabado, Anelise Espirito Santo, Martine Nagy. McGill Univer-
sity: Denise Avard. Halifax: IWK Health Centre: Margaret
Murray, Darlene Boliver, Marilyn Tiller, and Carol-Anne
Osborne. St. John’s: Janeway Children’s Hospital: Lisa Good-
year, Jack Hand and Lynette Bowes, and Norma Kean.
REFERENCES
1. Jones DP, Spunt SL, Green D, et al. Renal late effects in patients
treated for cancer in childhood: a report from the Children’s
Oncology Group. Pediatr Blood Cancer. 2008;51:724–731.
2. Lam AQ, Humphreys BD. Onco-nephrology: AKI in the cancer
patient. Clin J Am Soc Nephrol. 2012;7:1692–1700.
3. Oeffinger KC, Hudson MM. Long-term complications following
childhood and adolescent cancer: foundations for providing risk-
based health care for survivors. CA Cancer J Clin. 2004;54:208–236.
4. Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic
agents. Clin J Am Soc Nephrol. 2012;7:1713–1721.
5. Stava CJ, Jimenez C, Hu MI, et al. Skeletal sequelae of cancer and
cancer treatment. J Cancer Surviv. 2009;3:75–88.
6. Travis LB, Fossa SD, Sesso HD, et al. Chemotherapy-induced
peripheral neurotoxicity and ototoxicity: new paradigms for transla-
tional genomics. J Natl Cancer Inst. 2014:106.
7. DeConti RC, Toftness BR, Lange RC, et al. Clinical and pharmaco-
logical studies with cis-diamminedichloroplatinum (II). Cancer Res.
1973;33:1310–1315.
8. Marullo R, Werner E, Degtyareva N, et al. Cisplatin induces a
mitochondrial-ROS response that contributes to cytotoxicity depend-
ing on mitochondrial redox status and bioenergetic functions. PLoS
One. 2013;8:e81162.
9. Coradini PP, Cigana L, Selistre SG, et al. Ototoxicity from cisplatin
therapy in childhood cancer. J Pediatr Hematol Oncol. 2007;29:355– 360.
10. Miller RP, Tadagavadi RK, Ramesh G, et al. Mechanisms of
cisplatin nephrotoxicity. Toxins. 2010;2:2490–2518.
11. Skinner R, Pearson AD, English MW, et al. Cisplatin dose rate as a
risk factor for nephrotoxicity in children. Br J Cancer.
1998;77:1677–1682.
12. Fujieda M, Matsunaga A, Hayashi A, et al. Children’s toxicology
from bench to bed-drug-induced renal injury (2): nephrotoxicity
induced by cisplatin and ifosfamide in children. J Toxicol Sci.
Medicine  Volume 94, Number 34, August 201513. Cool WP, Grimer RJ, Carter SR, et al. Longitudinal growth
following treatment for osteosarcoma. Sarcoma. 1998;2:115–119.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.14. Stine KC, Wahl EC, Liu L, et al. Cisplatin inhibits bone healing
during distraction osteogenesis. J Orthop Res. 2014;32:464–470.
15. Gietema JA, Meinardi MT, Messerschmidt J, et al. Circulating
plasma platinum more than 10 years after cisplatin treatment for
testicular cancer. Lancet. 2000;355:1075–1076.
16. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for Disease
Control and Prevention 2000 growth charts for the United States:
improvements to the 1977 National Center for Health Statistics
version. Pediatrics. 2002;109:45–60.
17. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine
concentration for estimating glomerular filtration rate in infants,
children, and adolescents. Pediatr Clin North Am. 1987;34:571–590.
18. Kaplinsky C, Alon US. Magnesium homeostasis and hypomagnese-
mia in children with malignancy. Pediatr Blood Cancer.
2013;60:734–740.
19. National Kidney Foundation. KDOQI Clinical Practice Guideline for
Nutrition in Children with CKD: 2008 update. Executive summary.
Am J Kidney Dis. 2009;53:S11–104.
20. Arcara K, Tschudy M. The Harriet Lane Handbook: A Manual for
Pediatric House Officers/the Harriet Lane Service, Children’s
Medical and Surgical Center of the Johns Hopkins Hospital
Philadelphia, PA: Elsevier Mosby; 2012: 1132.
21. Acute Kidney Injury Work Group. KDIGO clinical practice for acute
kidney injury. Kidney Int Suppl. 2012;2:8–12.
22. Skinner R, Parry A, Price L, et al. Persistent nephrotoxicity during
10-year follow-up after cisplatin or carboplatin treatment in child-
hood: relevance of age and dose as risk factors. Eur J Cancer.
2009;45:3213–3219.
23. Ariceta G, Rodriguez-Soriano J, Vallo A, et al. Acute and chronic
effects of cisplatin therapy on renal magnesium homeostasis. Med
Pediatr Oncol. 1997;28:35–40.
24. Boskey AL. Bone composition: relationship to bone fragility and
antiosteoporotic drug effects. Bonekey Rep. 2013;2:447.
25. Abrams SA, Chen Z, Hawthorne KM. Magnesium metabolism in 4-
year-old to 8-year-old children. J Bone Miner Res. 2014;29:118–122.
26. Orchard TS, Larson JC, Alghothani N, et al. Magnesium intake, bone
mineral density, and fractures: results from the Women’s Health
Initiative Observational Study. Am J Clin Nutr. 2014;99:926–933.
27. Rude RK, Singer FR, Gruber HE. Skeletal and hormonal effects of
magnesium deficiency. J Am Coll Nutr. 2009;28:131–141.
28. Yokoo K, Murakami R, Matsuzaki T, et al. Enhanced renal
accumulation of cisplatin via renal organic cation transporter
deteriorates acute kidney injury in hypomagnesemic rats. Clin Exp
Nephrol. 2009;13:578–584.
29. Hjelle LV, Gundersen PO, Oldenburg J, et al. Long-term platinum
retention after platinum-based chemotherapy in testicular cancer survi-
vors: a 20-year follow-up study. Anticancer Res. 2015;35:1619–1625.
30. Filipski KK, Mathijssen RH, Mikkelsen TS, et al. Contribution of
organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxi-
city. Clin Pharmacol Ther. 2009;86:396–402.
31. Howell SB, Safaei R, Larson CA, et al. Copper transporters and the
cellular pharmacology of the platinum-containing cancer drugs. Mol
Pharmacol. 2010;77:887–894.
32. Motohashi H, Inui K. Multidrug and toxin extrusion family SLC47:
physiological, pharmacokinetic and toxicokinetic importance of
MATE1 and MATE2-K. Mol Aspects Med. 2013;34:661–668.
33. Pussegoda K, Ross CJ, Visscher H, et al. Replication of TPMT and
ABCC3 genetic variants highly associated with cisplatin-induced
Cisplatin Nephrotoxicity in Childrenhearing loss in children. Clin Pharmacol Ther. 2013;94:243–251.2009;34(Suppl 2):S251–S257.34. Wensing KU, Ciarimboli G. Saving ears and kidneys from cisplatin.
Anticancer Res. 2013;33:4183–4188.
www.md-journal.com | 7
